Key Highlights

  • PARADIGM reported a 7.92-point ALSFRS-R advantage at 18 months (about 36% slower decline, p=0.007) and a 14.9-month median survival benefit (HR 0.35, p=0.0037), but the 68-patient trial was explicitly not powered for definitive efficacy.
  • NeuroSense has FDA clearance to start the confirmatory Phase 3 PARAGON trial and, after a Pre-NDS meeting, intends to file a New Drug Submission with Health Canada in the coming months.
  • The company ended 2025 with about $166,000 in cash, a shareholders' deficit, recurring going-concern language and two Nasdaq deficiency notices with a September 29, 2026 compliance deadline.
  • The pivotal evidence behind NeuroSense Therapeutics stock (NRSN) is the Phase 2b PARADIGM trial (NCT05357950), a randomized, double-blind, placebo-controlled study run at ALS centers in Canada, Italy and Israel.

NeuroSense Therapeutics (NASDAQ:NRSN) is pushing its lead ALS candidate, PrimeC, toward a Canadian New Drug Submission after a Phase 2b study showed slower functional decline and a survival signal. The clinical story has strengthened through 2026, but it remains a small, thinly capitalized biotech carrying a Nasdaq listing deficiency, a shareholders' deficit and roughly $166,000 of cash at last count.

Why NeuroSense Is Back on Investors' Radar

NeuroSense Therapeutics Ltd. (NRSN), an Israeli clinical-stage biotechnology company based in Herzliya, has spent the first seven months of 2026 rolling out a string of updates on PrimeC, its combination therapy for amyotrophic lateral sclerosis (ALS). A March 16, 2026 announcement disclosed that the Phase 2b PARADIGM data had been published in JAMA Neurology. A June 29, 2026 release added a biomarker finding on TDP-43, the pathological hallmark of ALS. And on July 22, 2026, the company said it had held a "constructive" Pre-New Drug Submission meeting with Health Canada and intends to file a New Drug Submission (NDS) for PrimeC "in the coming months." Layered against that momentum is a stretched balance sheet: NeuroSense disclosed roughly $166,000 in cash at December 31, 2025, and in April 2026 it received formal Nasdaq deficiency notices.

That mix of scientific progress and financial fragility is what makes the stock's next few quarters consequential.

NeuroSense (NRSN): A Small Biotech Betting on a Repurposed Combination

NeuroSense's lead candidate, PrimeC, is a fixed-dose, extended-release oral combination of two already-approved generic drugs, ciprofloxacin and celecoxib, designed to act simultaneously on neuroinflammation, iron dysregulation and microRNA pathways implicated in ALS progression. The repurposing strategy is meant to shorten development timelines relative to a novel molecule, though it does not eliminate the need for standard efficacy and safety trials. Beyond ALS, the company has reported early biomarker signals from a Phase 2 Alzheimer's study, though those data are preliminary. As an Israeli company incorporated under the laws of the State of Israel, NeuroSense qualifies as a foreign private issuer and files annual reports on Form 20-F and current reports on Form 6-K, rather than the 10-K/10-Q schedule used by domestic filers; its most recent annual report was filed March 31, 2026 for fiscal year 2025.

The PrimeC Catalyst: What PARADIGM Actually Showed

The pivotal evidence behind NeuroSense Therapeutics stock (NRSN) is the Phase 2b PARADIGM trial (NCT05357950), a randomized, double-blind, placebo-controlled study run at ALS centers in Canada, Italy and Israel. It enrolled 68 participants, randomized 2:1 to PrimeC or placebo for a six-month blinded period, followed by a 12-month open-label extension in which all participants received PrimeC. Per the JAMA Neurology publication, continuously treated participants showed a 7.92-point advantage on the ALSFRS-R functional scale at 18 months, roughly a 36% slowing of disease progression (p=0.007), with the largest benefit in the bulbar domain governing speech and swallowing (p=0.001). Complication-free survival (avoiding respiratory failure, hospitalization or death) improved by a 64% relative risk reduction (p=0.02).

Longer-term follow-up disclosed in 2026 pointed to a 14.9-month median overall-survival benefit (hazard ratio 0.35, p=0.0037), roughly a 65% reduction in mortality risk. Separately, using a biomarker platform called ExoSORT from partner NeuroDex, NeuroSense reported PrimeC met a pre-specified biomarker endpoint: a significant reduction in neuron-derived TDP-43 versus placebo at day 180 (p=0.0421), widening by day 540 (p<0.001). NeuroSense's own investigators have acknowledged the trial "was not powered to demonstrate definitive efficacy": a standard limitation of a Phase 2b study with fewer than 70 patients, and the reason regulators require the larger, FDA-cleared Phase 3 PARAGON trial, expected to enroll about 300 ALS patients primarily in the U.S., before any approval decision.

Operating Trends: A Development-Stage Company With No Product Revenue

As a pre-commercial biotech, NeuroSense generates no product revenue; performance is measured in cash burn and trial progress. For fiscal 2025, R&D expense was $6.2 million, up from $5.7 million in 2024, and general and administrative expense was $4.9 million, up from $4.2 million, reflecting higher share-based compensation. Operating loss widened to $11.1 million from $9.9 million, and net loss was $11.1 million, or $0.44 per share, versus $10.2 million, or $0.54 per share, a year earlier. Shares outstanding grew from 23.2 million to 32.6 million during 2025, continuing a dilution trend that has taken the count from roughly 11.8 million in early 2023 to more than 32.5 million three years later.

Cash, Dilution and a Widening Balance-Sheet Strain

The clearest red flag in NeuroSense's disclosures is liquidity. At December 31, 2025, cash and cash equivalents stood at approximately $166,000, down from $3.4 million a year earlier, against total liabilities of $2.6 million, leaving a shareholders' deficit of $1.6 million versus positive equity of $2.6 million at the end of 2024. NeuroSense has funded operations through repeated shelf registrations (Form F-3), prospectus supplements, post-effective amendments to Form F-1, and a private-placement securities purchase agreement dated September 4, 2025. Going-concern language ("substantial doubt" about the company's ability to continue) recurs in its F-3 statements and Form 20-F annual reports, including the one filed March 31, 2026.

On April 3, 2026, Nasdaq notified NeuroSense that its shares had traded below the $1.00 minimum bid price for 30 consecutive business days and that its market value of listed securities had fallen below the required $35 million threshold; the company has until September 29, 2026 to regain compliance or face possible delisting.

Milestones That Could Move the Story

NeuroSense expects to file its Health Canada NDS "in the coming months" following the Pre-NDS meeting, with the agency's position on the pathway anticipated in the third quarter of 2026. Preparations continue for the FDA-cleared Phase 3 PARAGON trial, though NeuroSense has not disclosed a start date or funding plan for a study of that scale. Separately, in December 2024 NeuroSense announced a binding term sheet with an unnamed "leading global pharmaceutical company" covering ex-territory rights to PrimeC, including an upfront payment, Phase 3 funding, milestones and royalties, with a definitive agreement targeted for early 2025. A March 2025 filing said talks were continuing beyond that timeline; filings through July 2026 do not disclose a signed agreement, so the partnership should be treated as unresolved.

Outlook

The upside case rests on consistency: ALSFRS-R, survival, complication-free-survival and biomarker data have pointed the same direction, and peer review in JAMA Neurology adds validation. A completed licensing deal or positive Health Canada decision could change the funding outlook. The downside: a 68-patient, non-pivotal trial cannot substitute for confirmatory Phase 3 data, Health Canada has not ruled, the pharma partnership remains unsigned past its original target, and the company's cash position and going-concern disclosures raise real questions about funding Phase 3 without further dilution.

Conclusion

NeuroSense Therapeutics Ltd. (NRSN) has assembled a consistent Phase 2b data package in ALS, but PrimeC's fate still depends on a confirmatory Phase 3 trial, an unresolved Health Canada filing, and financing not yet secured. Investors weighing NRSN should separate the encouraging biomarker and survival signals from the unresolved regulatory and balance-sheet risks still facing the company.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.